Literature DB >> 7781666

Radioiodine therapy of Graves' hyperthyroidism: standard vs. calculated 131iodine activity. Results from a prospective, randomized, multicentre study.

H Peters1, C Fischer, U Bogner, C Reiners, H Schleusener.   

Abstract

The present prospective, randomized, multicentre study was performed to directly compare for the first time the effectiveness of a standard activity of 555 MBq 131iodine vs. an activity calculated to deliver 100 Gy for treatment of Graves' thyrotoxicosis. Therapeutic success was defined as the elimination of hyperthyroidism 6 months after radioiodine application (range 4.5-8 months). A success rate of more than 90% in eliminating hyperthyroidism was reported for both approaches, but only in retrospective investigations. Investigated prospectively, hyperthyroidism was eliminated in only 71% of the patients receiving standard activity (70/98) and 58% of those randomized for calculated activity (62/107). In the patients with standard activity, therapeutic success was inversely related to thyroid size. The rate was 100% for thyroid volumes < or = 15 mL, 95% for 16-30 mL, 68% for 31-45 mL, 44% for 46-50 mL, 20% for 61-75 mL and 25% for > or = 75 mL. In those patients with an activity calculated to deliver 100 Gy (except in those with a volume < or = 15 mL) this size/outcome dependency was almost compensated. The rates were 86%, 65%, 45%, 61%, 41% and 45%, respectively. Furthermore, detailed statistical analysis revealed a strong correlation between the success of therapy and the radiation dose actually absorbed by the thyroid. The rate was 11% for a target dose of 50 Gy, 50% for 100 Gy, 67% for 150 Gy, 80% for 200 Gy, 84% for 250 Gy, 88% for 300 Gy, 90% for 350 Gy and 93% for 400 Gy.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7781666     DOI: 10.1111/j.1365-2362.1995.tb01547.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  32 in total

1.  Change in the intrathyroidal kinetics of radioiodine under continued and discontinued antithyroid medication in Graves' disease.

Authors:  Simone Dunkelmann; Hubertus Kuenstner; Elham Nabavi; Bettina Rohde; Peter Groth; Carl Schuemichen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-09-22       Impact factor: 9.236

2.  Comparative Effectiveness of Treatment Choices for Graves' Hyperthyroidism: A Historical Cohort Study.

Authors:  Vishnu Sundaresh; Juan P Brito; Prabin Thapa; Rebecca S Bahn; Marius N Stan
Journal:  Thyroid       Date:  2017-02-06       Impact factor: 6.568

Review 3.  Controversies in the management of Graves' disease in children.

Authors:  S A Rivkees
Journal:  J Endocrinol Invest       Date:  2016-05-06       Impact factor: 4.256

4.  Outcome of treatment of hyperthyroidism.

Authors:  I M Bringmann; B L van Leeuwen; G Hennemann; G J Beckett; A D Toft
Journal:  J Endocrinol Invest       Date:  1999-04       Impact factor: 4.256

5.  Late and transient increases in free T4 after radioiodine treatment for Graves' disease.

Authors:  A D Stensvold; R Jorde; J Sundsfjord
Journal:  J Endocrinol Invest       Date:  1997-11       Impact factor: 4.256

6.  The route of administration (oral vs intravenous) does not influence dose or outcome in Graves' disease and unifocal autonomy.

Authors:  Peter Schneider; Johannes Biko; Heribert Hänscheid; Stephan Hilliger; Christos Koutsampelas; Michael Kranzfelder; Stephan Ladner; Christoph Reiners
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03-10       Impact factor: 9.236

7.  Current and emerging treatment options for Graves' hyperthyroidism.

Authors:  Prakash Abraham; Shamasunder Acharya
Journal:  Ther Clin Risk Manag       Date:  2010-02-02       Impact factor: 2.423

8.  Ultrasonography thyroid volume estimation in hyperthyroid patients treated with individual radioiodine dose.

Authors:  F Massaro; L Vera; M Schiavo; C Lagasio; M Caputo; M Bagnasco; F Minuto; M Giusti
Journal:  J Endocrinol Invest       Date:  2007-04       Impact factor: 4.256

Review 9.  Graves disease in childhood: a review of the options for diagnosis and treatment.

Authors:  Jorg Dötsch; Wolfgang Rascher; Helmuth G Dörr
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

10.  Radioiodine I-131 for the therapy of graves' disease.

Authors:  Malik Mumtaz; Lim Shueh Lin; Khaw Chong Hui; Amir Sharifuddin Mohd Khir
Journal:  Malays J Med Sci       Date:  2009-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.